Dr. Reddy’s inks pact with Cutis Pharma for API, drug research

07 Apr 2016 Evaluate

Dr. Reddy’s Laboratories has entered into active pharmaceutical ingredient (API) supply and joint development agreements with the US-based Cutis Pharma to advance several programs in Cutis Pharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

This partnership has significant strategic benefits for both the entities. Dr Reddy’s breadth of expertise and international infrastructure provide great synergy to Cutis Pharma’s own R&D and commercial organisations and will be a significant catalyst in its plans to fast-track the development of three of its programs towards new drug application (NDA) filings.

Cutis Pharma is a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, while Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

6321.25 -28.70 (-0.45%)
06-May-2024 09:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1518.95
Dr. Reddys Lab 6321.25
Cipla 1418.25
Zydus Lifesciences 990.45
Lupin 1640.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.